7 news items
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EQ
5 Jun 24
studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium's product candidates. These and other
Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
EQ
4 Jun 24
.
The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101 and signs of efficacy using Severity of Alopecia
Equillium Announces Topline Data From Phase 2 Study Of EQ101 In Alopecia Areata; 20% Of All Subjects That Completed The 24-week Treatment Period Achieved SALT ≤ 20; EQ101 Was Well Tolerated In Subjects With Alopecia Areata With No Serious Adverse Events Reported
EQ
4 Jun 24
were to evaluate the safety and tolerability profile of EQ101, as well as signs of efficacy using Severity of Alopecia Tool (SALT) scores, where a score
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
EQ
4 Jun 24
disease driven by an immune cell attack of the hair follicles that causes hair loss. The primary objectives of the study were to evaluate the safety
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
EQ
9 May 24
-pathogenic signaling. This approach is expected to avoid the broad immuno-suppression and off-target safety liabilities that may be associated with other
552qazmv6ioa3oflf42h tmpwj
EQ
7 May 24
studies; whether the results from clinical studies will validate and support the safety and efficacy of Equillium's product candidates
zjoze72e86nwbc32g34x6jwhb79574k1wfp582uw2z5gf
EQ
22 Mar 24
; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy
- Prev
- 1
- Next